Drug Trial Radar · NCT07491497
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 11, 2026
Primary completion
May 31, 2029
Study completion Jan 30, 2034
Sponsor
- Lead sponsor
- TRIANA Biomedicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication
Conditions
- ALK-positive NSCLC
- ALK-Positive Lung Cancer
- ALK-positive Non-small Cell Lung Cancer
Interventions
TRI-611Drug
oral ALK molecular glue degrader
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Treatment emergent adverse eventsTime frame: Within 28 days of the first TRI-611 dose
- Part 2: Objective response rate (ORR)Time frame: Approximately 16 weeks after the last participant dosed in Part 2
- Part 2: Depth of response (DofR)Time frame: Approximately 16 weeks after the last participant dosed in Part 2
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
UCSF
San Francisco, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Center
Boston, Massachusetts · Recruiting
Washington University Medical Center
St Louis, Missouri · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
University of Cincinnati Cancer Center
Cincinnati, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Oncology Consultants Research (P1 Trials)
Houston, Texas · Recruiting
START-Mountain Region
West Valley City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Royal North Shore Hospital
Sydney, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Gustave Roussy Institute
Villejuif, France · Recruiting
The Royal Marsden NHS Foundation
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.